AstraZeneca’s Lynparza (olaparib) Receives the US FDA’s Priority Review for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

 AstraZeneca’s Lynparza (olaparib) Receives the US FDA’s Priority Review for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca’s Lynparza (olaparib) Receives the US FDA’s Priority Review for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer

Shots:

  • The US FDA has accepted the sNDA for Lynparza and granted PR status based on P-III PROfound study assessing Lynparza vs hormonal agents (abiraterone or enzalutamide) in patients with HRR- mutated mCRPC who have progressed on prior therapies with new hormonal therapies including patients with BRCA1/2, ATM and CDK12 mutations
  • The P-III PROfound study results: 66% reduction in risk of disease progression or death; rPFS in patients with BRCA1/2- or ATM-mutated mCRPC (7.4 vs 3.6mos.); rPFS in the overall HRRm population (5.8 vs 3.5mos.)
  •  Lynparza (olaparib) is a first-in-class PARP inhibitor acts by targeting DNA damage response (DDR) in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation) with its expected PDUFA date in Q2’20

Click here to­ read full press release/ article | Ref: Astrazeneca | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post